NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand - Endpoints News
NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand - Endpoints News
Health
15 minutes ago 0 Views 05 Comment 1.5k Share
Listen to this article
0%
After tinkering with the biology of the broadly appealing anti-inflammatory NLRP3 pathway, NodThera is now plotting its pivotal trial plans for 2027.
We're not owned by a billionaire or shareholders — our readers support us. Choose to join with one of the options below. Cancel anytime.
Support any amount. Cancel anytime, no questions asked.
itnews.website & Media Limited
Privacy Policy
Your privacy is important. itnews.website collects information to process contributions. We use Stripe for secure payments. We never share your data without consent. For full details, visit https://itnews.website.
This is a demo integration with Stripe payment links.